Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
CX-4945: Practical CK2 Inhibition Workflows
2026-09-16
CX-4945 (Silmitasertib) provides a practical way to connect CK2 activity with apoptosis, cell-cycle control, stemness, and chemoresistance. This guide translates lung-cancer findings into matched cell models, target-engagement assays, and troubleshooting strategies for reproducible CK2 inhibition experiments.
-
Baricitinib for JAK1/2-STAT3 Assay Design
2026-09-15
Baricitinib (LY3009104) provides a selective pharmacological test of JAK1/2 dependence in IL-6- and IL-23-responsive systems. This workflow translates spatial PD-L1–IL-6 observations in primary sclerosing cholangitis into controlled cell, co-culture, and ex vivo experiments while separating pathway evidence from disease-model inference.
-
Sphingosine-1-phosphate: Practical Research Workflows
2026-09-15
Build more informative S1P experiments by pairing dose–time studies with receptor, kinase, and apoptosis readouts. This guide translates vascular, neuronal, and cell-survival applications into practical workflows while emphasizing fresh preparation, vehicle controls, and receptor-subtype validation.
-
Necrosulfonamide for MLKL Necroptosis Assays
2026-09-14
Necrosulfonamide helps separate upstream stress signaling from terminal MLKL-driven membrane rupture in necroptosis assays. This guide translates recent cardiac ischemia–reperfusion findings into practical workflows for dose selection, p-MLKL localization, calcium–mitochondrial readouts, and troubleshooting.
-
AMPK–JAK2/STAT3 Signaling in Obesity-Related Asthma
2026-09-14
The reference study identifies reduced AMPK activity and M1 macrophage polarization as linked features of obesity-related asthma, and places the JAK2/STAT3 pathway downstream of AMPK in this inflammatory context. Its combined mouse and RAW264.7-cell experiments support AMPK activation as a mechanistically informed direction for studying airway inflammation, while leaving clinical translation and reagent-specific effects to future work.
-
Okadaic acid (A4540): PP1/PP2A Workflow Guide
2026-09-13
Okadaic acid (A4540) provides a controlled way to reduce PP2A activity at low nanomolar concentrations and affect PP1 at higher concentrations, supporting phosphorylation and apoptosis experiments. It is best used in defined biochemical or cell-based studies with matched solvent controls, not as a broad-spectrum phosphatase inhibitor or as a direct substitute for cell-specific potency data.
-
Pleuromutilin Binding at the Ribosomal PTC
2026-09-12
The reference study combines chemical footprinting with ribosome resistance analysis to define how tiamulin and related pleuromutilins interact with the bacterial peptidyl transferase center. Its central implication is that conserved contacts from the mutilin core provide the binding framework, while derivative-specific side-chain interactions can influence resistance and guide rational antibiotic design.
-
Ruxolitinib Phosphate: From JAK Blockade to Cell Fate
2026-09-11
Ruxolitinib phosphate (INCB018424) is more than a proximal JAK1/2 inhibitor: research in anaplastic thyroid carcinoma connects JAK/STAT signaling pathway modulation with mitochondrial remodeling and distinct cell-death programs. This guide translates that finding into practical assay-design and interpretation decisions.
-
Rapamycin (Sirolimus) Workflows for mTOR Research
2026-09-11
Build reproducible mTOR perturbation experiments with Rapamycin (Sirolimus), from solvent handling and dose–response design to time-resolved signaling and disease-model interpretation. The workflow also distinguishes direct pathway inhibition from rapalog-triggered protein assembly, helping researchers select cleaner controls and more informative readouts.
-
Tofacitinib: From JAK Blockade to Mitochondrial Repair
2026-09-10
A mechanistic perspective on how Tofacitinib and CP-690550 connect JAK/STAT inhibition with GM-CSF-driven macrophage inflammation, mitochondrial dysfunction, and translational assay design in rheumatoid arthritis research.
-
Wortmannin Workflows for PI3K Signaling Research
2026-09-10
Wortmannin combines powerful PI3K pathway suppression with a practical way to interrogate endocytosis, autophagy, apoptosis, and cancer phenotypes. This workflow-focused guide connects pathway pharmacology with the reference study’s viral-entry assays while highlighting controls, dosing logic, and troubleshooting safeguards.
-
GSK2606414 for PERK-Driven ER Stress Research
2026-09-09
GSK2606414 is a high-potency PERK inhibitor for separating PERK-dependent signaling from broader ER stress responses. This practical guide translates a TMAO-induced zebrafish NAFLD study into cell-based, biochemical, and translational workflows with dosing, controls, and troubleshooting guidance.
-
SmCPK20–SmWRKY2 Control of Tanshinone Synthesis
2026-09-08
The reference study identifies a jasmonate–calcium signaling module in which SmCPK20 phosphorylates SmWRKY2 at Thr-256, increasing SmCPS1 promoter activation and tanshinone accumulation in Salvia miltiorrhiza. Its main contribution is to connect JAZ-mediated transcriptional release with a phosphorylation-dependent transcription-factor switch, providing a mechanistic framework for studying protein phosphorylation signaling in plant specialized metabolism.
-
Phosbind Acrylamide for Phosphorylation Analysis
2026-09-08
Phosbind Acrylamide enables antibody-free separation of phosphorylated and non-phosphorylated proteins by phosphate-dependent mobility shifts in SDS-PAGE. This guide connects the assay to inflammasome signaling research, offering an executable workflow, optimization checkpoints, and clear limits for interpreting phosphorylation evidence.
-
Stattic and the NF-κB–IL6–STAT3 Axis
2026-09-07
Stattic is a selective STAT3 inhibitor for studying how inflammatory signals drive tumor survival, resistance, and transcriptional reprogramming. This article translates findings from a gut dysbiosis–prostate cancer study into context-aware assay strategies for HNSCC research and cancer biology.